[ { "id": 1072, "name": "Silver", "slug": "silver", "former_names": [], "small_logo_thumb_url": "/company/thumb/missing.png", "website": "http://www.scansilver.com/", "all_locations": "San Francisco, CA, USA; Cupertino, CA, USA", "long_description": "At Silver, they are building the world's first miniaturized Raman spectroscope for consumers. Our spectroscope, combined with our proprietary nanoparticle substrates, enables our users to detect many contaminants instantaneously.", "one_liner": "Low cost consumer device for toxin detection. ", "team_size": 0, "industry": "Consumer", "subindustry": "Consumer -> Consumer Electronics", "launched_at": 1447748416, "tags": [ "Hard Tech", "Diagnostics", "Nanotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2016", "status": "Inactive", "industries": [ "Consumer", "Consumer Electronics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/silver", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2016/silver.json", "year_founded": null, "city": "San Francisco", "country": "US", "linkedin_url": null, "x_url": null, "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/silver", "github_url": null, "logo_url": null, "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 273, "full_name": "Victor Ng", "title": "Founder", "founder_bio": "Software Engineer ", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/vicngtor", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/101fd93fcf34ec0b7e46417e01e43394f24c7b6c.jpg" }, { "user_id": 112439, "full_name": "Peter Xian", "title": "Founder", "founder_bio": null, "is_active": true, "linkedin_url": "https://www.linkedin.com/pub/peter-xian/1a/830/80b", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/0ae3ffc7bdbc34d0137af19c7d11d058e0b2243d.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 1235, "name": "Shield Bio", "slug": "shield-bio", "former_names": [ "TL Biolabs", "Shield Diagnostics" ], "small_logo_thumb_url": "/company/thumb/missing.png", "website": "http://shieldbio.com", "all_locations": "San Francisco, CA, USA; San Jose, CA, USA", "long_description": "Shield Bio is a precision medicine company with a\r\nproprietary platform that enables reliable nanopore\r\nsequencing in under a minute, in a clinical setting. It is\r\nfocused on bringing 3rd generation or \"nanopore\"\r\nsequencing into clinical use to deliver on the promise of\r\nprecision medicine. Shield is initially using the technology to\r\nimprove the treatment of infectious disease and address the\r\nunmet clinical need of sepsis, which kills 300,000 people a\r\nyear in the US alone.", "one_liner": "Bringing 3rd generation, nanopore sequencing to healthcare to solve…", "team_size": 28, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1461210620, "tags": [ "Healthcare", "Genomics", "Nanotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2016", "status": "Inactive", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/shield-bio", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2016/shield-bio.json", "year_founded": null, "city": "San Francisco", "country": "US", "linkedin_url": null, "x_url": "", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/tl-biolabs", "github_url": null, "logo_url": null, "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 135686, "full_name": "Fred Turner", "title": "Founder/CEO", "founder_bio": "", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/fred-turner-70688776", "x_url": "https://twitter.com/FredTurnerBio", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/24846d3e66271106d7d5d967ea6f89429cc7313c.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 1504, "name": "Arylla", "slug": "arylla", "former_names": [ "Arylla Inc." ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/625cc8316448d38d73101072829a6b5898adf51f.png", "website": "http://www.arylla.com", "all_locations": "Kitchener, ON, Canada", "long_description": "Arylla has created a printable tag that can be scanned with any phone using our API. We piggyback on legacy commercial printers to get our tag onto products at scale and license our API to developers who build services on top of our tag. We are 10x less expensive and much more scalable than alternatives like NFC.", "one_liner": "We connect products to the internet using an invisible, chip-less tag", "team_size": 6, "industry": "Industrials", "subindustry": "Industrials -> Manufacturing and Robotics", "launched_at": 1478577033, "tags": [ "IoT", "Nanotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2017", "status": "Inactive", "industries": [ "Industrials", "Manufacturing and Robotics" ], "regions": [ "Canada", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/arylla", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2017/arylla.json", "year_founded": 2016, "city": "Kitchener", "country": "CA", "linkedin_url": "", "x_url": "https://twitter.com/Arylla_Inc", "fb_url": "https://www.facebook.com/aryllainc/", "cb_url": "https://www.crunchbase.com/organization/arylla", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/625cc8316448d38d73101072829a6b5898adf51f.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 158446, "full_name": "Perry Everett", "title": "Founder/Business Development", "founder_bio": "", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/perry-everett-77402176", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/911fca6f1d1b227df440a86c10d289bc95a434cc.jpg" }, { "user_id": 159688, "full_name": "Benjamin Rasera", "title": "Founder", "founder_bio": null, "is_active": true, "linkedin_url": "https://www.linkedin.com/in/benjamin-rasera-814b8547?trk=nav_responsive_tab_profile", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/87c532543c6d04ff745714b6761bd4bd04537f8d.jpg" }, { "user_id": 158491, "full_name": "Graham Thomas", "title": "Founder", "founder_bio": null, "is_active": true, "linkedin_url": "https://ca.linkedin.com/in/graham-thomas-25b6328a", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/a3f902e20721c6178138ba9521aa766ebebade5d.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 1560, "name": "Helix Nanotechnologies", "slug": "helix-nanotechnologies", "former_names": [ "Helix Nanotechnologies" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/f05a634de42c2c96484608b63b33b99fd27aa56e.png", "website": "http://helixnano.com", "all_locations": "Boston, MA, USA; Cambridge, MA, USA", "long_description": "Technology finds information and delivers physical products to us almost instantly. mRNA does the same for biology. At HelixNano, we see a world where treatments are cheap, progress is decentralized, and you can modify biology at the push of a button.\r\n\r\nBy focusing on mRNA improvements from first principles, we’re getting there faster than we thought. Experiments that used to take months or years can be done in weeks and cost thousands instead of millions. The rate limiting step for our progress is now scientific curiosity.\r\n\r\nRigid hierarchies and top-down decisions will miss the magic. Some of our most powerful technologies started out as side projects of junior team members. At HelixNano, every individual scientist can have a massive impact on the company's direction. And the more diverse our team, the faster we’ll find the really cool ideas.\r\n\r\nWe've started rolling out some of our new tech — moving a COVID-19 vaccine candidate for the immunocompromised towards the clinic, and testing an intervention with massive environmental impact. But we’re scientists at heart, and team focus is solidly on the horizon.", "one_liner": "Next-generation mRNA platform to solve cancer, COVID and climate.", "team_size": 22, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1482443417, "tags": [ "Biotech", "Genomics", "Nanotechnology", "AI" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2017", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/helix-nanotechnologies", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2017/helix-nanotechnologies.json", "year_founded": null, "city": "Boston", "country": "US", "linkedin_url": "", "x_url": "http://twitter.com/helixnano", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/helixnano", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/f05a634de42c2c96484608b63b33b99fd27aa56e.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 173672, "full_name": "Nikolai Eroshenko", "title": "Founder/CSO", "founder_bio": null, "is_active": true, "linkedin_url": "https://www.linkedin.com/in/nikolai-eroshenko-668998119", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/f1d37eb73289b63509a03de868d65f0202150337.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 12664, "name": "Kern Systems", "slug": "kern-systems", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/960f475f7529b916c176fbf83565873d60242a91.png", "website": "https://www.kernsystems.com", "all_locations": "Boston, MA, USA", "long_description": "DNA has emerged as a compelling data storage medium due to its density, longevity, and eternal relevance compared to current memory technologies. However, the high price of synthesizing DNA remains a major bottleneck for adoption of this promising storage solution. We are pioneering new approaches to synthesizing DNA for data storage with enzymes and custom digital codecs. We are building an interdisciplinary team to build the world's most scalable information infrastructure in DNA. \r\n\r\nWe seek technical experts in enzyme engineering, chemistry, hardware engineering, and information theory. We also seek business development to identify emerging markets for early use cases of our technology.", "one_liner": "Using DNA to store data.", "team_size": 3, "industry": "Healthcare", "subindustry": "Healthcare -> Industrial Bio", "launched_at": 1556764621, "tags": [ "Genomics", "Nanotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2019", "status": "Active", "industries": [ "Healthcare", "Industrial Bio" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/kern-systems", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2019/kern-systems.json", "year_founded": null, "city": "Boston", "country": "US", "linkedin_url": "", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/960f475f7529b916c176fbf83565873d60242a91.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 208492, "full_name": "Henry Lee", "title": "Founder", "founder_bio": "Interested in deep-tech. BS-EE@UW, PhD-BioE@BU, and Postdoc-Genetics@Harvard.", "is_active": false, "linkedin_url": "https://www.linkedin.com/in/hhlee/", "x_url": "https://twitter.com/hhlee", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/df22de19c6b26415f0a25128aef33633f48ade68.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 12666, "name": "spotLESS Materials", "slug": "spotless-materials", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/f4bcbe21be5fc35568846a259c348e3973168839.png", "website": "https://www.industry.spotlessmaterials.com", "all_locations": "State College, PA, USA", "long_description": "Surface fouling is a costly challenge across industries, impacting medical consumables, diagnostic devices, and automotive components. Contamination from substances like mud, ice, and sludge can compromise performance and lead to frequent cleaning, repairs, and replacements.\r\n\r\nOur PFAS-free coating, which we first launched as a consumer product, has quickly expanded into industrial partnerships. It dramatically reduces contamination on critical surfaces such as glass, metal, ceramic, and now plastics too. Whether for medical devices or automotive components, our coating protects against surface fouling\r\nCurrently our coatings work best on glass, metal, and ceramic surfaces. ", "one_liner": "Repellent coatings without PFAS", "team_size": 6, "industry": "Industrials", "subindustry": "Industrials", "launched_at": 1556766727, "tags": [ "Hard Tech", "Nanotechnology", "Advanced Materials" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2019", "status": "Active", "industries": [ "Industrials" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/spotless-materials", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2019/spotless-materials.json", "year_founded": 2018, "city": "State College", "country": "US", "linkedin_url": "https://www.linkedin.com/company/69636574/", "x_url": "https://twitter.com/spotlessCoating", "fb_url": "https://facebook.com/spotless.materials", "cb_url": "https://www.crunchbase.com/organization/spotless-materials", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/f4bcbe21be5fc35568846a259c348e3973168839.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 308278, "full_name": "Birgitt Boschitsch", "title": "Founder", "founder_bio": "", "is_active": true, "linkedin_url": "https://linkedin.com/in/birgitt-boschitsch/", "x_url": "https://twitter.com/birgittmb", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/598b64ace3008fc9a98c96b621118f781ebb11de.jpg" }, { "user_id": 330790, "full_name": "Tak-Sing Wong", "title": "Founder", "founder_bio": null, "is_active": true, "linkedin_url": "https://www.linkedin.com/in/tak-sing-wong-6b35a7b/", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/9381cf5db967b997bb283125f66d972e060a66bd.jpg" } ], "jobs": [], "news": [ { "title": "This Magic Spray Prevents Your Toilet From Getting Skid Marks. You’re Welcome. | Reviews by Wirecutter", "url": "https://www.nytimes.com/wirecutter/reviews/spotless-materials-toilet-coating-review/", "date": "Oct 01, 2024" }, { "title": "Spotless Materials raises $1.6M seed to address PFAS", "url": "https://www.axios.com/pro/retail-deals/2024/08/19/spotless-materials-seed-raise-pfas", "date": "Aug 19, 2024" }, { "title": "SpotLESS Materials experiences growth selling super slippery coating technology | Penn State University", "url": "https://www.psu.edu/news/invent-penn-state/story/spotless-materials-experiences-growth-selling-super-slippery-coating/", "date": "Jan 27, 2022" }, { "title": "This super-slippery toilet coating saves water by repelling poop - Fast Company", "url": "https://www.fastcompany.com/90432084/this-new-magical-coating-saves-water-by-making-toilets-so-slippery-that-poop-basically-flushes-itself", "date": "Jun 29, 2021" }, { "title": "Superslippery Toilets Squash Water Wastage - Scientific American", "url": "https://www.scientificamerican.com/article/superslippery-toilets-squash-water-wastage/", "date": "Jun 29, 2021" } ], "launches": [] }, { "id": 13506, "name": "Nomic Bio", "slug": "nomic-bio", "former_names": [ "nplex biosciences" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/d3005075624cbc032b9abdd1525e6ec3201158f5.png", "website": "http://www.nomic.bio", "all_locations": "Montreal, QC, Canada", "long_description": "Nomic is doing for protein profiling, what Illumina did for DNA sequencing. Our core technology, the nELISA, is a next-gen immunoassay platform that transforms the ELISA into a high-throughput, high-content, and high-versatility tool. \r\n\r\nToday we developed the nELISA for high-throughput drug discovery scientists, enabling them profile 100s of proteins at 10x higher throughput and 10x lower cost compared to existing solutions. We're offering the nELISA through early access programs to HTS groups in top pharmas as well as pioneering biotechs in the space.\r\n\r\nOur goal is to create a ubiquitous technology that consolidates the broad range of legacy immunoassay toolkits that scientists use today with a single platform that can carry the science end-to-end, from discovery all the way to the clinic. \r\n\r\nWe're a team of engineers, biologists, and highly-skilled lab operators that are looking to grow quickly to keep up with customer demand but also to continue developing our core technology, scale our multiplexing/throughput, and build our software stack. We're hiring on a number of positions including engineering, software, biology, and ops. Come talk to us!", "one_liner": "Nomic is doing for proteins what Illumina has done for DNA", "team_size": 100, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1583898031, "tags": [ "Nanotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Winter 2020", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "Canada", "America / Canada", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/nomic-bio", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2020/nomic-bio.json", "year_founded": 2017, "city": "Montreal", "country": "CA", "linkedin_url": "https://www.linkedin.com/company/nomicbio", "x_url": "https://twitter.com/nomicbio", "fb_url": null, "cb_url": null, "github_url": "https://github.com/nplexbio", "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/d3005075624cbc032b9abdd1525e6ec3201158f5.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": { "name": "Jared Friedman", "url": "https://www.ycombinator.com/people/jared-friedman" }, "founders": [ { "user_id": 348069, "full_name": "Milad Dagher", "title": "Founder", "founder_bio": null, "is_active": true, "linkedin_url": "https://www.linkedin.com/in/milad-dagher/", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/5e9b665b6c0e06ad38db091c0a3dcf258fdb1474.jpg" }, { "user_id": 284722, "full_name": "Jeff Munzar", "title": "Founder", "founder_bio": null, "is_active": true, "linkedin_url": "https://www.linkedin.com/in/jeffmunzar/", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/1a58ed2964c881b15c185864b39a05e0edf32114.jpg" } ], "jobs": [ { "id": 67109, "title": "Data Engineer", "url": "https://www.ycombinator.com/companies/nomic-bio/jobs/djdcWbI-data-engineer", "location": "Remote (United States) / Remote (US)", "type": "Full-time", "role": "Engineering", "role_type": "Full stack", "salary_range": "", "equity_range": "", "experience": "", "visa": "US citizen/visa only", "skills": [] }, { "id": 67110, "title": "Software Engineer (Jr to Sr Levels)", "url": "https://www.ycombinator.com/companies/nomic-bio/jobs/fQPrFFq-software-engineer-jr-to-sr-levels", "location": "Remote (United States) / Remote (US)", "type": "Full-time", "role": "Engineering", "role_type": "Full stack", "salary_range": "", "equity_range": "", "experience": "", "visa": "US citizen/visa only", "skills": [] }, { "id": 67111, "title": "R&D Lab Associate", "url": "https://www.ycombinator.com/companies/nomic-bio/jobs/tvcDSbW-r-d-lab-associate", "location": "Montreal", "type": "Full-time", "role": "Operations", "role_type": null, "salary_range": "", "equity_range": "", "experience": "", "visa": "US citizen/visa only", "skills": [] }, { "id": 67112, "title": "Data Associate", "url": "https://www.ycombinator.com/companies/nomic-bio/jobs/xPOgeWa-data-associate", "location": "Remote (United States) / Remote (US)", "type": "Full-time", "role": "Operations", "role_type": null, "salary_range": "", "equity_range": "", "experience": "", "visa": "US citizen/visa only", "skills": [] } ], "news": [ { "title": "Nomic collects $17M to advance its automated, high-throughput ELISA platform | FierceBiotech", "url": "https://www.fiercebiotech.com/medtech/nomic-collects-17m-to-advance-its-automated-high-throughput-elisa-platform", "date": "Dec 08, 2021" } ], "launches": [] }, { "id": 25151, "name": "Keylika", "slug": "keylika", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/bd12fc4dc5d053441f31a9c528579e0d16f3449e.png", "website": "https://www.keylika.com", "all_locations": "San Francisco, CA, USA; Walnut Creek, CA, USA", "long_description": "Keylika is an early stage biopharma startup developing metal-based drugs using a platform synthesis technology to treat unmet medical needs. We then administer these drugs using proven delivery technologies to effect the best clinical outcomes. \r\n\r\nOur first product is a small molecule iron drug (new molecular entity) delivered by a wearable skin patch to treat Iron Deficiency Anemia (IDA), with significantly higher safety, efficacy and tolerability over existing treatments. This is poised to be a best-in-class, potentially breakthrough therapy for treating iron deficiency without any GI side-effects (eg. nausea, constipation, diarrhea, etc.) typically associated with oral iron supplements, and without the risks, costs and side-effects associated with IV iron infusions. When approved, Keylika’s proprietary transdermal iron will be the world's first prescription iron patch. Iron deficiency is a hugely understated problem affecting about 1.6 billion people worldwide and more than 30 million in the US alone, translating to a $17B US market.", "one_liner": "Redefining the Standard of Care for Iron Deficiency Anemia", "team_size": 1, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1658519436, "tags": [ "AI-powered Drug Discovery", "Medical Devices", "Drug Delivery", "Nanotechnology", "Therapeutics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2022", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": true, "app_answers": [ { "question": "Describe what your company does in 50 characters or less.", "answer": "We develop metallodrugs for unmet medical needs." } ], "question_answers": null, "url": "https://www.ycombinator.com/companies/keylika", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2022/keylika.json", "year_founded": 2022, "city": "San Francisco", "country": "US", "linkedin_url": "https://www.linkedin.com/company/keylika/", "x_url": "https://twitter.com/keylika_inc", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/bd12fc4dc5d053441f31a9c528579e0d16f3449e.png", "app_video_url": null, "dday_video_url": "https://bookface-images.s3.us-west-2.amazonaws.com/video_event/58/1662662980325-y62ohje1s2-e76deefbbfbb2fb38de30a62b84546d9/714326f49aba38f91fda71a9c6d47471.mp4?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIAQC4NIECABPQ2AHNW%2F20261020%2Fus-west-2%2Fs3%2Faws4_request&X-Amz-Date=20261020T022701Z&X-Amz-Expires=3600&X-Amz-SignedHeaders=host&X-Amz-Signature=658b0a7fb2ce8bd68597d0a5076c7260b1d48c3c6ffdde07533bb121cf26ce6b", "company_photos": [], "primary_partner": { "name": "Jared Friedman", "url": "https://www.ycombinator.com/people/jared-friedman" }, "founders": [ { "user_id": 756768, "full_name": "Buddha Chaudhuri", "title": "Founder", "founder_bio": "Buddha spearheaded the technology development of a microneedle-based biosensor from lab-to-fab for a Series B stage medtech startup. Having worked across 3 continents and 6 countries, he has been instrumental in developing novel healthcare technologies in leading global research institutes and biotech companies, for the last 15 years. \n\nBuddha earned his PhD from Imec / KU Leuven in Belgium, in Drug Delivery Microsystems. He also pursued a Postdoc at UC San Francisco (UCSF) / UC Berkeley. ", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/buddhadevpc", "x_url": "https://twitter.com/buddhachaudhuri", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/8e4a1a5185f5455f05b9967fc8793797c729bd4c.jpg" }, { "user_id": 776586, "full_name": "Frederik Ceyssens", "title": "Founder", "founder_bio": "With a deep passion for diverse technologies, I'm a true multi-domain expert. My interest go from tiny moving machines to nuclear space rockets, from electrical circuits to medical devices and beyond. Next to Keylika, I founded ReVision, a neurotech company aiming at restoring sight in blind people, developing widely useful high-res neurotech in the process.\n\nI have an EE PhD, a MSc. in IC design as well as a BSc. in Medicine. ", "is_active": true, "linkedin_url": "http://linkedin.com/in/frederik-ceyssens-43b6ab5", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/20288d3198cb324772987da4da9b7f8137d8a725.jpg" } ], "jobs": [], "news": [ { "title": "Keylika Develops World's First Buccal Patch for Iron Deficiency Anemia (IDA) | Entrepreneur", "url": "https://www.entrepreneur.com/en-au/news-and-trends/keylika-develops-worlds-first-buccal-patch-for-iron/490791", "date": "Apr 29, 2025" }, { "title": "Keylika develops first Buccal Patch for Iron Deficiency Anemia (IDA) - Arabian Business: Latest News on the Middle East, Real Estate, Finance, and More", "url": "https://www.arabianbusiness.com/industries/healthcare/keylika-develops-first-buccal-patch-for-iron-deficiency-anemia-ida", "date": "Apr 25, 2025" }, { "title": "Bootstrapped Indian Startup Innovating Treatment for Eczema, Itch & Beyond | Entrepreneur", "url": "https://www.entrepreneur.com/en-in/news-and-trends/bootstrapped-indian-startup-innovating-treatment-for/490293", "date": "Apr 20, 2025" }, { "title": "TACKLING IRON-DEFICIENCY ANAEMIA: A LEAP FORWARD WITH A REVOLUTIONARY BUCCAL PATCH - ONdrugDelivery", "url": "https://www.ondrugdelivery.com/tackling-iron-deficiency-anaemia-a-leap-forward-with-a-revolutionary-buccal-patch/", "date": "Jun 17, 2024" }, { "title": "Bootstrapping in Biotech: How Keylika’s Founding Story Highlights Key Entrepreneurship Lessons", "url": "https://www.usatoday.com/story/special/contributor-content/2024/05/12/bootstrapping-in-biotech-how-keylikas-founding-story-highlights-key-entrepreneurship-lessons/73665473007/", "date": "May 12, 2024" } ], "launches": [ { "id": 64959, "title": "Keylika: Redefining the Standard of Care for Iron Deficiency", "tagline": "World's first prescription iron patch to treat Iron Deficiency Anemia", "body": "[Keylika](https://www.keylika.com) is combining its **metallodrug synthesis technology** with **optimized delivery methods** to obtain improved clinical outcomes. Our first product is a **novel iron drug** in a **wearable skin patch** with significantly improved safety, efficacy and tolerability to treat **Iron Deficiency Anemia (IDA).** When approved, Keylika’s proprietary transdermal iron will be the **world's first** prescription iron patch.\n\n### **The Problem**\n\n**Iron Deficiency Anemia (IDA) is a hugely understated, highly prevalent problem with subpar treatments.**\n\nIron deficiency (ID) affects **30 million** people in the US alone and about **1.6 billion** worldwide. Current treatments include oral iron supplements which are typically associated with low bioavailability and poor tolerability due to mild to severe gastrointestinal (GI) side-effects (constipation, nausea, stomach discomfort, diarrhea, etc.) often leading to patient non-compliance. Also, a significant number of patients just do not absorb iron taken orally.  The second line of treatment with intravenous (IV) iron infusions is more invasive, riskier, costlier and requires hospitalization due to the risk of anaphylactic shocks.\n\n### **Our Solution**\n\nOur first product is a **new small molecule (new molecular entity)**, an **iron-containing drug** designed for **transdermal** delivery by a wearable skin patch: **NistuFe**. It is a safe, highly bioavailable iron complex with higher efficacy. A therapeutically relevant dosage is administered through the skin directly into the systemic circulation, thereby circumventing the gastrointestinal tract and all associated adverse effects. Thus, we combine the benefits of both orals and IV iron, and without their respective downsides: a drug suitable for self-administration with no GI side effects and no required hospitalization that yields a superior treatment outcome from the convenience of a patient’s home. This is slated to be a potentially **best-in-class, breakthrough therapy**. Our preliminary proof-of-concept in vivo studies in rats have demonstrated excellent results.\n\n![uploaded image](/media/?type=post&id=64959&key=user_uploads/756768/c93eab67-c28a-45c2-8a20-42843bbd0d16)\n\n### **Our Science**\n\nAt our core is a **platform synthesis technology** we have developed for synthesizing mixed ligand metal complexes. We are using this platform to generate a range of drug candidates for treating therapeutic conditions in the fields of hematology, pain and inflammation, metabolic disorders, infectious diseases and oncology. We then administer these drugs using proven delivery technologies, to effect the best clinical outcomes. Positioned at the **intersection of drug development and drug delivery**, we customize the molecular structure of the drug and its formulation to optimize the therapeutic delivery per clinical requirements.\n\n### **Target Population**\n\nOur first indication being menorrhagia, our primary target population is **women of child-bearing age** in the US who suffer from severe to moderate ID, which has an estimated prevalence of 6 million. A wide range of other patient groups adds up to a potential **30 million** users in the US alone.\n\n### **Our Ask**\n\n1\\.     If you know anyone in your social circle suffering from Iron Deficiency, we would love to talk to them!\n\n2\\.     If you are connected to biopharma companies with interests in the hematology space, could you please introduce us?\n\nPlease follow us on [LinkedIn](https://www.linkedin.com/company/keylika/)!\n\nQuestions? Feel free to reach out: [founders@keylika.com](mailto:founders@keylika.com)", "url": "https://www.ycombinator.com/launches/Gtj-keylika-redefining-the-standard-of-care-for-iron-deficiency", "votes": 59, "created_at": "2022-07-28T02:09:46.908Z" } ] }, { "id": 28112, "name": "Persist AI", "slug": "persist-ai", "former_names": [ "Persist AI", "Persist AI Formulations Corp" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/eeb1e38a6ca6e6061c101deae73f22c28c142596.png", "website": "http://www.persist-ai.com", "all_locations": "Sacramento, CA, USA", "long_description": "It takes 5 years for pharma to develop long lasting drug injections for chronic diseases like cancer and diabetes. Persist uses AI-driven automation to reduce formulation development time down to 2 years, a ~50% reduction.", "one_liner": "Developing long-lasting drug formulations 50% faster", "team_size": 6, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1671420729, "tags": [ "Machine Learning", "Robotics", "Microfluidics", "Nanotechnology", "Therapeutics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2023", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": true, "demo_day_video_public": true, "app_answers": [ { "question": "Describe what your company does in 50 characters or less.\n", "answer": "Help pharma develop slow release drugs faster" }, { "question": "What is your company going to make? Please describe your product and what it does or will do.\n", "answer": "For a pharma company to develop a sustained-release (slow release) drug formulation takes about 3-5 years and $10M or more. This is because there are a lot of variables and scientists' intuition (aka guesswork) needed to arrive at the final formulation solution.\r\n\r\nWe will provide a service to pharma companies to develop their formulations for them 50% faster and cheaper than current methods. To do this we will screen formulations in high throughput using automation and train ML which can make better predictions based on data (rather than guesses).\r\n\r\nThis will enable pharma companies to get drugs to market faster and earn revenue sooner." } ], "question_answers": null, "url": "https://www.ycombinator.com/companies/persist-ai", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2023/persist-ai.json", "year_founded": 2022, "city": "Sacramento", "country": "US", "linkedin_url": "https://www.linkedin.com/company/persist-ai/", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/eeb1e38a6ca6e6061c101deae73f22c28c142596.png", "app_video_url": "https://bookface-images.s3.us-west-2.amazonaws.com/bf-public_profile/28167/app_video.mp4?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=ASIAQC4NIECAOMAGS7ZB%2F20261020%2Fus-west-2%2Fs3%2Faws4_request&X-Amz-Date=20261020T022712Z&X-Amz-Expires=60&X-Amz-Security-Token=IQoJb3JpZ2luX2VjEHEaCXVzLXdlc3QtMiJHMEUCIG5%2FEuPdHreXKRdGLYlyC2AjaYHPccvwucNqtFtDJEpNAiEAs4s5lSDOcogMQrwGhSKvVJXgimMvlIc1KK%2Fa7hojYD4q5QMIOhAAGgwwMDYyMDE4MTEwNzIiDMPa%2BQzgV8CSsX3XwyrCA9yWuwhv7VPDGJqPM%2BDoevlHz47k5lLRdgsGITLyqtSgmLV07z1Y86XDlb4dZMfcWmY5u5FLutDaUy2PMJ92q6vIq41n2jI5tC6SNSed8Qx%2Frdr9Wotko6WcUJWENt0Rs1K4pKZ8ZHCjH22BoWJkWLaTQ8fDKsmgWu0C8NMhnc8i44rKtbZLOvQwKZIlI546tkfyyliSiXPWdZ4XhGxEegateXp4TnM4yWfebpv22hrRHRotmFYX8ANU3B8yiEQL9yrU1y10N8c42JlHR%2FXHZNxaFQqX6eENp2aa2yewya2kPgdiQ3efnk5d0LiuPYxk7ZBa6uOug4fCBPHurDSGZqOlYX9D4h6PAMyUN2kZw2IcUR9QWKM2BmEsGorqokH5Oe34gs0DmnOGrGbhANOh9LKlKDu%2B6Pc4U%2F8L3%2Bmxug0q%2B3JBUGE7Wf6ySj%2B%2BbW8eOteynPrtIEUsD0pcfnSFNzQepsmnoTP5xc7qG%2FEn4MNWO3TviPmcIdg9qyW7bwOWKSyly4BuerWbZWVxIVolnUdqKu2PxDrgnb41QrRtObgKLlbhdehgPlqhIVqZ1cWH9s2uGHoiWlN5FRY8vYYodKzLGjDn%2FdrWBjqlAdXY8WsF5AC2X79ObZ%2FmZD1gjSCNFddCxk1e7RhQVznesCZJDMryJDWqJGSqI7lLEk62aPqOUbquB9Ghba%2BJXI%2FUV%2BHgkJZAPy7wzbnv8vLB8WccujudilaH29xgpqopxweKHuQzlcRMMeq0SZHCo3PizMnbhtLrqB%2BiK9IdfwMp8c15fBnQEe2RAGCsOWYNCrhsPiR6yT5V9698E5KnRPYRfOeFQw%3D%3D&X-Amz-SignedHeaders=host&X-Amz-Signature=c66d7d91c1532ade147f60b6506c8084f0b87596e1d90190def0886579506001", "dday_video_url": "https://bookface-images.s3.us-west-2.amazonaws.com/video_event/60/1680881229067-tn5frveent9-fbed84ada9379d7720a00b6d13e1f184/ba402ea2758b4d68f29d058ba99cd408.mp4?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIAQC4NIECABPQ2AHNW%2F20261020%2Fus-west-2%2Fs3%2Faws4_request&X-Amz-Date=20261020T022712Z&X-Amz-Expires=3600&X-Amz-SignedHeaders=host&X-Amz-Signature=69e456b3a0e858aa28c02639034baef60514627411b140d9fa05f425a7d41c39", "company_photos": [], "primary_partner": { "name": "Jared Friedman", "url": "https://www.ycombinator.com/people/jared-friedman" }, "founders": [ { "user_id": 1094851, "full_name": "Karthik Raman", "title": "Founder", "founder_bio": "When mom got brain cancer, I used to take her for her \"infusions\". \n\nFor 4 hours, we would sit there while drug was being infused into her veins and she had horrible nausea and hair loss.\n\nI built Persist to eradicate this horrible experience for future patients. \n\nWe package drugs so that patients take 1 injection per month or year, without an infusion. This lowers the overall dose the patient receives (reducing side-effects), improves compliance, and quality of life. ", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/karthik-raman-scientist/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/ecc2a524e445309696a536435506c40bc98010ac.jpg" }, { "user_id": 1114143, "full_name": "Christopher Shelner", "title": "Founder", "founder_bio": "Career program manager, first time founder. Focus has been in electronics, automation, and manufacturing. Super excited to be part of the YC batch! ", "is_active": true, "linkedin_url": "http://www.linkedin.com/in/christophershelner/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/25ae4aac51df1a910d1efc90c169f83830fc6913.jpg" } ], "jobs": [], "news": [ { "title": "Beyond the $12M: Revolutionizing Drug Formulation Development at Persist AI", "url": "https://www.persist-ai.com/post/beyond-the-12m-revolutionizing-drug-formulation-development-at-persist-ai", "date": "May 19, 2025" }, { "title": "Persist AI Raises $4M in Seed Financing to Revolutionize Drug Formulation ", "url": "https://www.persist-ai.com/post/persist-ai-raises-4m-in-seed-financing-to-revolutionize-drug-formulation", "date": "Aug 04, 2023" } ], "launches": [ { "id": 69239, "title": "Persist - We build long-lasting drugs 50% faster 💊", "tagline": "Drug formulations made by robotics and designed by AI", "body": "### **TLDR**\n\nPersist helps pharma make drug injections that last up to 1 year. \n\nUsing robotics & AI, we reduce a 5-year drug formulation process to \\~2 years.\n\n**Contact Us (**[**founders@persist-ai.com**](mailto:founders@persist-ai.com)**) for a case-study formulation**\n\nTo make injections we encapsulate drugs inside injectable microspheres made with FDA-approved materials.\n\n![uploaded image](/media/?type=post&id=69239&key=user_uploads/1094851/19542a20-d5f0-4ccd-9450-d6b8427a6b94)\n\n**_Left:_** _Image of a \\~37 um microsphere made by our robotics_\n\n**_Right:_** _A Schematic showing how encapsulated drugs are released over 1 year so patients don’t take as many injections._\n\n### 🤔**THE PROBLEM**\n\nFor chronic diseases, most patients prefer 1 injection/yr rather than multiple injections per week.\n\nHowever, making a long-lasting injection takes a lot of trial and error and the time between iterations is long.\n\nKey challenges include:\n\n* **Using manual work & intuition is slow**: Typical teams manually mix and match chemicals to optimize the amount of drug that’s loaded into the spheres and the rate of release of drug\n* **Trial and error is cumbersome:** Because changing one variable may have multiple effects \n* **Scale-up is unpredictable:** Even if something works at a small scale, batch-to-batch consistency during scale-up is uncertain because production is done in large reactors\n\n### 💡**OUR SOLUTION**\n\nWe utilize custom robotics and AI to solve the problems with building microspheres. \n\n* **We automatically mix & optimize formulations:** We use a closed-loop robotics + AI approach so there’s minimal manual work\n* **We reduce trial & error with AI predictions:** We generate 50x more data than most formulation teams and use that data to train AI. This unique data enables us to make better predictions than others.\n* **We build small batches, faster:** So we can QC batches more frequently and scale up predictably\n\n### ❤️**OUR ASKS**\n\nIntroduce us to friends who work in Pharma. Email [founders@persist-ai.com](mailto:founders@persist-ai.com) \n\n“Follow” us [on LinkedIn](https://www.linkedin.com/company/persist-ai/)", "url": "https://www.ycombinator.com/launches/I0l-persist-we-build-long-lasting-drugs-50-faster", "votes": 36, "created_at": "2023-02-13T16:43:58.890Z" } ] }, { "id": 28159, "name": "Invitris", "slug": "invitris", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/b31c6e14e61e0a7e292383c88d7094914a492565.png", "website": "https://invitris.com/", "all_locations": "Munich, BY, Germany", "long_description": "Invitris radically simplifies how we create novel biological drugs. Our patent-pending technology platform turns DNA into synthetic proteins and was recently featured in the Science magazine. It makes creating new drugs >10,000x more efficient at <100x lower costs of material.\r\n\r\nOur killer application is enabling the newest generation of synthetic bacteriophages to combat antibiotic-resistant infections, which are threatening to cause more deaths than all cancers combined. ", "one_liner": "Creating new protein-based drugs at scale", "team_size": 6, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1678475135, "tags": [ "Biotech", "Nanotechnology", "Drug discovery" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2023", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "Germany", "Europe", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/invitris", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2023/invitris.json", "year_founded": 2022, "city": "Munich", "country": "DE", "linkedin_url": "https://www.linkedin.com/company/invitris/", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/b31c6e14e61e0a7e292383c88d7094914a492565.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 1163538, "full_name": "Patrick Grossmann", "title": "Founder", "founder_bio": "My hearts are entrepreneurship & science, originally trained as bioinformatician at the Harvard Medical School and ETH Zurich amongst other schools. I earned a PhD and MBA, and highly enjoy opportunities to improve the world with science-based products. I co-founded Invitris to radically simplify drug development to stop antibiotic-resistance, which has the potential to become the dominating health-economic challenge in this century.", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/patrickgrossmannbioinformatics/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/7fd393675a42df3ca1abac5c1131e3248a325274.jpg" }, { "user_id": 1195343, "full_name": "Kilian Vogele", "title": "Founder", "founder_bio": "Kilian, the CTO and co-founder of Invitris, is responsible for driving innovation and development within the company. With a PhD in synthetic biology from TUM and a track record of 5 patents, his expertise has been instrumental in creating Invitris' groundbreaking technology.", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/kilian-vogele-21a321183/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/4cb832abbb78ced414d19e28f010a711ebeb3ece.jpg" } ], "jobs": [], "news": [ { "title": "Innovation and Start-up Center Biotechnology (IZB) welcomes Invitris - Innovations- und Gründerzentrum Biotechnologie IZB", "url": "https://www.izb-online.de/en/media-library/press-release/press-release-izb-martinsried/innovation-and-start-up-center-biotechnology-izb-welcomes-invitris/", "date": "Feb 28, 2023" }, { "title": " moma future: Viren gegen Bakterien - ZDFheute", "url": "https://www.zdf.de/nachrichten/zdf-morgenmagazin/moma-future-viren-gegen-bakterien-100.html", "date": "Feb 06, 2023" }, { "title": "Bacteriophages the Modern Way | Science | AAAS", "url": "https://www.science.org/content/blog-post/bacteriophages-modern-way", "date": "Aug 17, 2022" } ], "launches": [ { "id": 70166, "title": "INVITRIS - Simplifying drug development & manufacturing", "tagline": "Our biotech platform creates the newest drugs in shortest time", "body": "### **Tl;dr**\n\nAt Invitris we're creating **protein-based drugs**, such as the next generation of antibiotics. To do this at scale, we created a platform called **Phactory**, that can turn DNA into synthetic proteins. Phactory makes the development of novel protein-based drugs 10,000x more efficient and cuts down the material costs by 100x.\\\n—\n\nHi everyone! This is [**Kilian** ](https://www.linkedin.com/in/kilian-vogele-21a321183/)and [**Patrick**](https://www.linkedin.com/in/patrickgrossmannbioinformatics/) from INVITRIS, a Munich-based life science company.\n\n![uploaded image](/media/?type=post&id=70166&key=user_uploads/89898/df875741-b00f-4ba8-b56f-48cee390fbf1)\n\n# **Protein-based drugs are powerful but expensive**\n\nWhile only 2% of all treatments are based on protein-based drugs, these drugs generate 40% of the total drug revenue. One of the reasons why they are so expensive is that you need living cells, like bacteria, to produce them. **Handling living cells is error-prone** and **scales terribly** because you have to establish new processes for every new drug.\n\n# **One platform to synthesize them all**\n\nOur universal biotech platform, **Phactory**, takes DNA and uses it to synthesize proteins in a single step. It mimics the molecular machinery you find in living cells but can be stored in conventional vessels.\n\n![uploaded image](/media/?type=post&id=70166&key=user_uploads/1163538/e720da18-e212-42d5-9a13-a5e53fbecc80)\n\nThis platform is based on Kilian’s groundbreaking research during his PhD, which was honored in the famous magazine [**Science** ](https://www.science.org/content/blog-post/bacteriophages-modern-way)and was also featured on [**German national TV**](https://www.zdf.de/nachrichten/zdf-morgenmagazin/moma-future-viren-gegen-bakterien-100.html)!\n\nOur primary focus area is **bacteriophages** - natural viruses that cannot attack humans but bacteria, even when those have become resistant to antibiotics. We are therefore tackling a problem that is expected to cause 25% more deaths per year than all cancers combined in the next decades: [multidrug-resistant infections](https://www.stopamr.eu/blog/new-studies/no-more-wake-up-calls-amr-is-now-the-leading-cause-of-death-worldwide/).\n\n# **We believe in collaboration and partnering!**\n\nBuilding new protein-based products is hard. We can help each other.\n\n* We are constantly looking for **biopharmaceutical partners** seeking innovation!\n* Intros to companies developing antibacterial products in animal health or agriculture are also welcome!\n* If you **struggle with protein synthesis** in general - we can help!\n* Know anyone who is experienced in scaling cell-free expression under GMP? Reach out!\n\nAny outreach is highly appreciated:\n\n![uploaded image](/media/?type=post&id=70166&key=user_uploads/1163538/d016e457-3a55-4651-a7f6-6308d85772cb)\n\n", "url": "https://www.ycombinator.com/launches/IFi-invitris-simplifying-drug-development-manufacturing", "votes": 45, "created_at": "2023-03-10T22:48:50.259Z" } ] } ]